The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Highlights in colorectal cancer from ESMO WCGIC 2022
Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA, comments on two main highlights in the field of colorectal cancer (CRC) from ESMO WCGIC 2022. Prof. Lenz discusses the positive findings from an open-label, Phase I, multicenter study (NCT03860272) in which an Fc-engineered anti-CTLA-4 human monoclonal antibody (botensilimab) was used in combination with a PD-1 inhibitor (balstilimab) for the treatment of refractory cancer. Prof. Lenz also comments on the Phase II MOUNTAINEER trial (NCT03043313) in which tucatinib, a HER-2 inhibitor, in combination with trastuzumab showed high efficacy for the treatment of refractory CRC. The implications of the findings from these two trials are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
Disclosures
Ad Boards/Lectures: BMS, Roche, Oncocyte, Fulgent, Bayer, G1 Therapeutics, Jazz Therapeutics, Abbvie, Merck, Merck KG, Isofol
Clinical Trial Support: NCI, NIH, SWOG, Isofol, Pfizer, BMS, G1 Therapeutics, Cardiff, Amal-KISIMA, Mirati, Merck, Bayer, Idera, UCB, PsOxius, NGM, OBI Pharma
